Enhancer-targeted genome editing selectively blocks innate resistance to oncokinase inhibition.
about
Making sense of GWAS: using epigenomics and genome engineering to understand the functional relevance of SNPs in non-coding regions of the human genomeDicer-microRNA-Myc circuit promotes transcription of hundreds of long noncoding RNAs.Can genome engineering be used to target cancer-associated enhancers?A LncRNA-MAF:MAFB transcription factor network regulates epidermal differentiation.Mitf is a master regulator of the v-ATPase, forming a control module for cellular homeostasis with v-ATPase and TORC1.TFAP2 paralogs regulate melanocyte differentiation in parallel with MITF.The Long Non-Coding RNA MEG3 is an Epigenetic Determinant of Oncogenic Signaling in Functional Pancreatic Neuroendocrine Tumor Cells.From profiles to function in epigenomics.The master role of microphthalmia-associated transcription factor in melanocyte and melanoma biology.Beyond MITF: Multiple transcription factors directly regulate the cellular phenotype in melanocytes and melanoma.SH3BP4, a novel pigmentation gene, is inversely regulated by miR-125b and MITF.OCT4 impedes cell fate redirection by the melanocyte lineage master regulator MITF in mouse ESCsTranscription factors as critical players in melanoma invasiveness, drug resistance, and opportunities for therapeutic drug development.Noncanonical hedgehog pathway activation through SRF-MKL1 promotes drug resistance in basal cell carcinomas.Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.Role of HGF-MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer.A direct link between MITF, innate immunity, and hair graying.
P2860
Q26771497-E05F4E96-522E-4F9B-8E99-73F86D315BADQ33902641-72DBC53C-258F-44FA-9910-9EE5DC51E3FEQ34652242-FF42BCA6-5EEF-45A7-96B5-54C6C88312C3Q35684575-12021A09-E768-453F-8A69-A55AF68142BDQ35968782-1353C158-7172-49C6-9DA8-1F902A9CDEF2Q36294018-534F5F85-1741-4FCE-BB0B-CD3EADC15F14Q38694016-AFE1A3EC-0D13-4497-B662-F8E3735FB52CQ39014872-9B5110B5-D681-426A-B20B-997599F35FB0Q39163758-D4897E15-1438-47F0-96A9-AE2C529AC17BQ39397994-A23F4F17-06FE-4E5D-B21D-C66EF6771305Q41583239-C211C289-1D23-4626-A5A7-2E3B87F61B24Q42380162-3928505A-DDBD-4052-A154-1A0ABC1FF541Q48090844-77F4CE5C-194A-4F2E-B1BB-2622888DE05DQ48106107-DBBD422E-0CF0-403C-8D53-07D754750422Q48863076-78A7F588-6189-42FE-AC3C-EDBF64017732Q53711253-D937D05B-4373-4536-8169-72C31BA9218AQ54959863-EE7EE986-8FF0-4D76-A2B4-A661B8EDE37A
P2860
Enhancer-targeted genome editing selectively blocks innate resistance to oncokinase inhibition.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Enhancer-targeted genome editi ...... ance to oncokinase inhibition.
@en
Enhancer-targeted genome editi ...... ance to oncokinase inhibition.
@nl
type
label
Enhancer-targeted genome editi ...... ance to oncokinase inhibition.
@en
Enhancer-targeted genome editi ...... ance to oncokinase inhibition.
@nl
prefLabel
Enhancer-targeted genome editi ...... ance to oncokinase inhibition.
@en
Enhancer-targeted genome editi ...... ance to oncokinase inhibition.
@nl
P2093
P2860
P356
P1433
P1476
Enhancer-targeted genome editi ...... ance to oncokinase inhibition.
@en
P2093
Ashley Zehnder
Brook Barajas
Dan E Webster
Joanna Kovalski
Karen J Yan
Paul A Khavari
Poornima H Neela
Rose T Bussat
Ross J Flockhart
P2860
P304
P356
10.1101/GR.166231.113
P577
2014-01-17T00:00:00Z